Durvalumab

Lohankhapedia (自由的百科全書) 欲共你講..。
跳至導覽 跳至搜尋
Immunotherapy: mechanism of action for Durvalumab， Pembrolizumab，Ipilimumab， Atezolizumab 。Adapted from: First line Immunotherapy for Non-Small Cell Lung Cancer。 Nasser NJ， Gorenberg M， Agbarya A。 Pharmaceuticals 2020， 13(11)， 373 https://doi.org/10.3390/ph13110373


Durvalumab [1] 以 (í)Imfinzi品排 (phín-pâi)銷售 (siau-siū)，是 (sī)FDA批准 (phue-tsún)的 (ê)癌症 (gâm-tsìng)免疫 (bián-i̍k)療法 (liâu-huat)，由 (iû)Medimmune/AstraZeneca所 (sóo)開發 (khai-huat).[2]Durvalumab是一 (tsi̍t)t種 (tsióng)人類 (jîn-luī)免疫球卵白 (kiû-nn̄g-pe̍h)G1 kappa (IgG1κ) 單 (tuann)clone抗體 (khòng-thé)，會當 (ē-tàng)阻斷 (tsóo-tn̄g)程食性 (tîng-sū-sìng)細胞 (sè-pau)死亡 (sí-bông)配體 (phuè-thé)1 (PD-L1) 和 (hām)PD-1 (CD279) 个 (ê)互相 (hōo-siong)作用 (tsok-iōng)。 Durvalumab是一種 (tsi̍t-tsióng)免疫檢查點 (kiám-tsa-tiám)抑制劑 (ik-tsè-tsè)藥物 (io̍h-bu̍t).[3]

註解 (Tsù-kái)[修改]

  1. ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (Iⁿ). Proposed Iⁿ: List 112" (PDF). WHO Drug Information. 28 (4). goân-loē-iông (PDF) tī 28 August 2021 hőng khó͘-pih. 6 September 2022 khòaⁿ--ê.  Unknown parameter |url-status= ignored (help)
  2. ↑ "Durvalumab (Imfinzi)". U.S. Food and Drug Administration (FDA). goân-loē-iông tī 8 May 2017 hőng khó͘-pih. 2017-05-06 khòaⁿ--ê.  Unknown parameter |url-status= ignored (help)
  3. ↑ Syn NL，丁MW， Mok TS，蘇RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.  Vancouver style error: initials (help)

參閱 (Tsham-ua̍t)[修改]

  • Atezolizumab (Tecentriq)
  • Avelumab (Bavencio)

外部 (Guā-pōo)連結 (liân-kiat)[修改]

來源: "https://taigi.lohankhapedia.org/w/index.php?title=Durvalumab&oldid=3069340"